|
|
Volumn 30, Issue 4, 2002, Pages 512-516
|
|
Formatting antibody fragments to mediate specific therapeutic functions
a
a
UCB PHARMA
(Belgium)
|
|
Author keywords
Manufacture; Valency
|
|
Indexed keywords
ANTIGEN;
COMPLEMENT;
FC RECEPTOR;
IMMUNOGLOBULIN F(AB')2 FRAGMENT;
IMMUNOGLOBULIN F(AB) FRAGMENT;
IMMUNOGLOBULIN FC FRAGMENT;
IMMUNOGLOBULIN FRAGMENT;
IMMUNOGLOBULIN G;
IMMUNOGLOBULIN G1;
IMMUNOGLOBULIN G2;
IMMUNOGLOBULIN G4;
MONOCLONAL ANTIBODY;
ANTIBODY AFFINITY;
ANTIBODY ENGINEERING;
ANTIBODY SPECIFICITY;
ANTIBODY STRUCTURE;
ANTIGEN BINDING;
CELL KILLING;
CELL TYPE;
COMPLEMENT ACTIVATION;
CONFERENCE PAPER;
COST;
CYTOLYSIS;
CYTOTOXICITY;
DRUG DELIVERY SYSTEM;
DRUG EFFECT;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG MECHANISM;
DRUG TARGETING;
EFFECTOR CELL;
EXPRESSION VECTOR;
HUMAN;
INFECTION;
INFLAMMATION;
MICROORGANISM;
NONHUMAN;
ONCOLOGY;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN FUNCTION;
PROTEIN MODIFICATION;
ANTIBODIES, MONOCLONAL;
ANTIBODY-DEPENDENT CELL CYTOTOXICITY;
HUMANS;
IMMUNOGLOBULIN FRAGMENTS;
IMMUNOGLOBULIN G;
INTERLEUKIN-1;
RECOMBINANT PROTEINS;
STRUCTURE-ACTIVITY RELATIONSHIP;
VECTORS;
|
|
EID: 0036670529
PISSN: 03005127
EISSN: None
Source Type: Journal
DOI: 10.1042/BST0300512 Document Type: Conference Paper |
|
Times cited : (65)
|
|
References (17)
|
